LifeMD’s $47.3 million revenue result comes with a grim forecast
- LifeMD reported Q2 2026 revenue of $47.3 million and an adjusted EBITDA loss of about $3.5 million.
- LifeMD shares fell 5.8% to $3.68 after the company lowered its full-year revenue and earnings forecasts.
- The company is shifting patients toward longer subscriptions, branded GLP-1 therapies, pharmacy services and new healthcare partnerships.
LifeMD (NASDAQ:LFMD) reported Q2 2026 revenue of $47.3 million and cut its full-year outlook after recording a $3.5 million adjusted EBITDA loss.
Revenue declined from $49 million a year earlier, while adjusted EBITDA moved from a $3.9 million profit to a $3.5 million loss.
Gross margin rose to about 89%, active subscribers reached 356,000, and cash stood at $25.1 million with no debt.
Following the announcement, LifeMD's share price was down 5.8% at $3.68 in premarket trading.
LifeMD said about 95% of new weight-management patients now start branded GLP-1 treatments as it expands pharmacy, women’s health and XYOSTED services.
The company now forecasts 2026 revenue of $205.5 million to $212.5 million and adjusted EBITDA between a $6 million loss and breakeven.
Frequently asked questions
More from United States
Amazon Q3 revenue accelerates 12% to $201.9 billion as AWS growth accelerates
Intel Q3 revenue skyrockets 21% to $16.5B as data center sales surge
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
